港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

維立志博-B

54.400

-8.050-12.89%

成交量：1,086.42萬

成交額：6.17億

市值：108.26億

市盈率：-38.81

高：62.750

開：61.300

低：51.750

收：62.450

52周最高：97.500

52周最低：44.720

股本：1.99億

香港流通股本：1.98億

量比：25.44

換手率：5.49%

股息：- -

股息率：- -

每股收益(LYR):-1.402

淨資產收益率：-27.61%

總資產收益率：-9.92%

市淨率：7.38

市盈率(LYR):-38.81

市銷率: 52.72

資料載入中...

總覽公司新聞公告

維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)獲納入優先審評審批程序用於治療晚期肺外神經內分泌癌

維立志博-B獲NMPA優先審評資格　PD-L1/4-1BB雙抗維利信™衝刺EP-NEC首款上市藥物

【券商聚焦】華源證券首予維立志博(09887)買入評級看好核心管線潛力

維立志博-B 2026年6月股份變動月報表，股本總數保持198,891,800股

維立志博-B(09887)：根據H股獎勵計劃授出合共225.47萬份獎勵

智通财经网

維立志博－Ｂ(09887)股價下跌5.255%，現價港幣$46.52

阿斯达克财经

H股全流通、早期股東解禁與存倉異動，腰斬後的維立志博-B(09887)是否值博？

智通港股早知道 | 兩部門發布《新型能源體系建設「十五五」規劃》五部門聯合啓動2026年新能源汽車下鄉活動

維立志博宣佈合作伙伴Oblenio Bio完成超額認購的6200萬美元B輪融資，推進自身免疫疾病三特異性T細胞銜接器Lbl-051進入臨床開發

維立志博-B完成B輪融資，輝瑞風投領投，Deep Track Capital、GV與Aditum Bio跟投

維立志博-B(09887.HK):Oblenio完成超額認購6200萬美元B輪融資，加速LBL-051的臨床開發

維立志博-B(09887)完成44,391,598股未上市股份轉換為H股，已發行股本增至197,670,289股

維立志博-B(09887)存倉市值總計14.86億港元股東將2584.62萬股股票存入中國證券登記結算香港

維立志博-B5月股份變動月報表：股本維持不變

維立志博(09887.HK)維利信臨床研究結果入選世界肺癌大會口頭報告

阿斯达克财经

維立志博-B(09887)：受託人擬根據H股獎勵計劃收購最高5000萬美元H股

智通财经网

維立志博-B授出信託人指令，以最高5000萬美元購買H股作為獎勵計劃

港股異動 | 維立志博-B(09887)早盤升逾4% 維利信™治療晚期肺外神經內分泌癌III期臨床研究獲批

維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)治療晚期肺外神經內分泌癌的III期臨床研究獲得CDE批准

一周港股牛熊榜 | 金輝控股飆152%領跑，京西國際、天岳先進升逾六成強勢爆發

老虎资讯综合

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09887/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"維立志博-B","latestPrice":54.4,"timestamp":1785122199797,"preClose":62.45,"halted":0,"volume":10864200,"delay":0,"changeRate":-0.12890312249799846,"floatShares":198000000,"shares":199000000,"eps":-1.4017318339371696,"marketStatus":"交易中","change":-8.05,"latestTime":"07-27 11:16:47","open":61.3,"high":62.75,"low":51.75,"amount":616677997,"amplitude":0.176141,"askPrice":54.5,"askSize":1300,"bidPrice":54.4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.3635027839207015,"tradingStatus":2,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1785124800000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":62.45,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":25.442757,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.401833,"volumeRatio":25.442757,"shares":199000000,"dividePrice":0,"high":62.75,"amplitude":0.176141,"preClose":62.45,"low":51.75,"week52Low":44.72,"pbRate":"7.38","psRate":"52.72","week52High":97.5,"institutionHeld":0,"latestPrice":54.4,"committee":-0.857143,"eps":-1.4018327399344388,"divideRate":0,"volume":10864200,"delay":0,"ttmEps":-1.3636009379362268,"open":61.3,"prevYearClose":51,"prevWeekClose":62.45,"prevMonthClose":49.32,"prevQuarterClose":49.32,"fiveDayClose":64.45,"twentyDayClose":49.58,"sixtyDayClose":81.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-07-24","current":-45.804107,"percent":0.258197,"low":-76.458084,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"high":-30.202688,"avg":-41.824579,"sd":10.124459,"marketCap":12420792910},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910}],"updateTime":1785101828994},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650901516","title":"維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)獲納入優先審評審批程序用於治療晚期肺外神經內分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901516","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650901516?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 12:32","pubTimestamp":1783657957,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，维利信单药治疗晚期肺外神经内分泌癌的生物制品上市许可申请，已获中华人民共和国国家药品监督管理局药品审评中心批准纳入优先审评审批程序。根据相关中国法规，获纳入优先审评审批程序的BLA审评时限为130个工作日，而常规审评程序则为200个工作日。维利信获纳入优先审评程序标志着其迈向商业化的重要里程碑，为其预期获批时间表提供了明确指引及确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1169589451.USD","09887","LU1169590202.USD","HK0000252152.HKD","HK0000252160.HKD","BK4023","HK0000500386.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134216700","title":"維立志博-B獲NMPA優先審評資格　PD-L1/4-1BB雙抗維利信™衝刺EP-NEC首款上市藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=1134216700","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134216700?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 12:31","pubTimestamp":1783657890,"startTime":"0","endTime":"0","summary":"2026年7月10日，维立志博-B公布，其自主研发的PD-L1/4-1BB双特异性抗体奥帕替苏米单抗单药用于治疗晚期肺外神经内分泌癌的生物制品上市许可申请，获国家药品监督管理局药品审评中心纳入优先审评审批程序。根据中国现行法规，优先审评BLA的审评时限为130个工作日，较常规200个工作日显著缩短。公司提醒投资者，依据香港联交所证券上市规则第18A.05条，维利信仍处于监管审评阶段，无法保证最终能成功上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649988702","title":"【券商聚焦】華源證券首予維立志博(09887)買入評級 看好核心管線潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2649988702","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649988702?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 16:37","pubTimestamp":1783413472,"startTime":"0","endTime":"0","summary":"、研报核心看好公司管线LBL-024成为下一代IO 2.0基石药物的潜力。考虑到公司在肿瘤及自免领域的深度布局及临床管线的有序推进，首次覆盖给予“买入”评级。主要风险包括临床研发失败、竞争格局恶化、销售不及预期及行业政策风险。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985266","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","09887","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115028409","title":"維立志博-B 2026年6月股份變動月報表，股本總數保持198,891,800股","url":"https://stock-news.laohu8.com/highlight/detail?id=1115028409","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115028409?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 17:09","pubTimestamp":1782983392,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司于2026年7月2日披露截至2026年6月30日的证券变动月报表。报告期内，公司法定注册股本由期末的人民币198,891,800元保持不变，各类股份总数维持198,891,800股。报告期内，H股由上月底的153,278,691股增加44,391,598股，本月底结存为197,670,289股；未上市股份由上月底的45,613,109股减少44,391,598股，本月底结存1,221,511股。截至2026年6月30日，公司总股本保持为198,891,800股，相关事项均符合适用的法律法规及上市规则。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648154843","title":"維立志博-B(09887)：根據H股獎勵計劃授出合共225.47萬份獎勵","url":"https://stock-news.laohu8.com/highlight/detail?id=2648154843","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648154843?lang=zh_tw&edition=fundamental","pubTime":"2026-07-01 20:17","pubTimestamp":1782908274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2026年7月1日，本公司根据H股奖励计划向149名受让人授出合共225.47万份奖励，惟须待受让人接纳后方可作实。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","09887","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646528335","title":"維立志博－Ｂ(09887)股價下跌5.255%，現價港幣$46.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2646528335","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646528335?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 11:34","pubTimestamp":1782444840,"startTime":"0","endTime":"0","summary":"[下跌股]维立志博－Ｂ(09887) 股价在上午11:33比前收市价下跌5.255%，现股价为港币$46.52。至目前为止，今日最高价为$48.76，而最低价为$46.52。总成交量为11.9万股，总成交金额为港币$565.288万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2606265175/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2606265175/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646287380","title":"H股全流通、早期股東解禁與存倉異動，腰斬後的維立志博-B(09887)是否值博？","url":"https://stock-news.laohu8.com/highlight/detail?id=2646287380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646287380?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 09:54","pubTimestamp":1782438888,"startTime":"0","endTime":"0","summary":"同样在4月16日，维立志博-B盘中股价达到97.50港元，创下上市新高。随着其完成H股全流通以及早期股东解禁期即将到来，维立志博能否抵住这轮场内抛压成为投资者关注的焦点。H股全流通、早期股东解禁与存仓异动拉长时间线来看，维立志博股价今年3-4月实现87.71%的涨幅，其核心驱动力来自产品管线突破与市场流动性改善的双重加持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646384975","title":"智通港股早知道 | 兩部門發布《新型能源體系建設「十五五」規劃》 五部門聯合啓動2026年新能源汽車下鄉活動","url":"https://stock-news.laohu8.com/highlight/detail?id=2646384975","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646384975?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 07:15","pubTimestamp":1782429349,"startTime":"0","endTime":"0","summary":"国家发改委、国家能源局发布《新型能源体系建设“十五五”规划》智通财经APP获悉，6月25日，国家发改委、国家能源局发布《新型能源体系建设“十五五”规划》，其中提到，加快氢能与绿色燃料产业发展。截至2026年2月 28日止财政年度，来自耐克产品线上销售的收","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","BK1613","BK4585","VXUS","09879","BK1227","HK0000320264.USD","HK0000306701.USD","09887","HK0000165453.HKD","HK0000252160.HKD","LU1808992512.USD","BK1615","HK0000500386.USD","02696","BK1574","BK1589","HK0000320223.HKD","BK1113","HK0000252152.HKD","02616","03998","BK1109","00020","80020","BK1512","BK1502","BK1500","LU1675838814.USD","HK0000306685.HKD","159945"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188451308","title":"維立志博宣佈合作伙伴Oblenio Bio完成超額認購的6200萬美元B輪融資，推進自身免疫疾病三特異性T細胞銜接器Lbl-051進入臨床開發","url":"https://stock-news.laohu8.com/highlight/detail?id=1188451308","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188451308?lang=zh_tw&edition=fundamental","pubTime":"2026-06-25 18:43","pubTimestamp":1782384204,"startTime":"0","endTime":"0","summary":"维立志博宣布，其合作伙伴Oblenio Bio成功完成了一轮超额认购的B轮融资，融资额达6200万美元。此次融资将用于推进其针对自身免疫疾病的三特异性T细胞衔接器Lbl-051进入临床开发阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195591415","title":"維立志博-B完成B輪融資，輝瑞風投領投，Deep Track Capital、GV與Aditum Bio跟投","url":"https://stock-news.laohu8.com/highlight/detail?id=1195591415","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195591415?lang=zh_tw&edition=fundamental","pubTime":"2026-06-25 18:42","pubTimestamp":1782384143,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司近日成功完成B轮融资。本轮融资由辉瑞旗下的风险投资部门辉瑞风投领投，Deep Track Capital、GV以及Aditum Bio共同参与投资。维立志博-B是一家专注于肿瘤免疫治疗及自身免疫性疾病领域创新抗体药物研发的生物技术公司。辉瑞风投的领投，结合Deep Track Capital、GV和Aditum Bio等专业投资机构的共同参与，彰显了资本市场对维立志博-B研发平台与技术潜力的高度认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","BK4599","BK4588","HK0000252152.HKD","IE00B3T34201.USD","LU0225284248.USD","LU1883839398.USD","LU0321505868.SGD","BK4534","LU1066053197.SGD","LU1057294990.SGD","LU0868494617.USD","LU0306807586.USD","BK4592","IE0002270589.USD","SG9999011175.SGD","09887","LU0234572021.USD","PFE","LU1894683348.USD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4550","LU2596442595.SGD","LU0122379950.USD","IE000M9KFDE8.USD","BK4533","HK0000500386.USD","LU0225771236.USD","LU0456855351.SGD","LU1066051498.USD","IE00B19Z3B42.SGD","SG9999001176.USD","LU0170899867.USD","LU0058720904.USD","LU0306806265.USD","SG9999013999.USD","IE00B19Z3581.USD","BK1161","LU0289739699.SGD","BK4585","LU0985481810.HKD","LU1894683264.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","LU0321505439.SGD","SG9999003800.SGD","BK4007","BK4568","LU1023059063.AUD","HK0000252160.HKD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646187973","title":"維立志博-B(09887.HK):Oblenio完成超額認購6200萬美元B輪融資，加速LBL-051的臨床開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2646187973","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646187973?lang=zh_tw&edition=fundamental","pubTime":"2026-06-25 18:04","pubTimestamp":1782381842,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185914600","title":"維立志博-B(09887)完成44,391,598股未上市股份轉換為H股，已發行股本增至197,670,289股","url":"https://stock-news.laohu8.com/highlight/detail?id=1185914600","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185914600?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 19:30","pubTimestamp":1780659015,"startTime":"0","endTime":"0","summary":"2026年6月5日，维立志博-B(09887)发布翌日披露报表，宣布公司于2026年6月4日将44,391,598股未上市股份转换为H股。根据公告，这部分转换股份约占转换前公司已发行股本（不包括库存股份）153,278,691股的28.96%，本次变动后，公司于香港联交所上市的H股总数增至197,670,289股。\n同时，公告显示，对应未上市股份数量由原先的45,613,109股降至1,221,511股，此次转换股数占该部分未上市股份变动金额的比例约为97.32%。\n公司在公告中确认已取得董事会正式授权，且相关转换符合所有适用的上市规则与法律法规。公告由联席公司秘书左洪刚签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维立志博-B(09887)完成44,391,598股未上市股份转换为H股，已发行股本增至197,670,289股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641193294","title":"維立志博-B(09887)存倉市值總計14.86億港元 股東將2584.62萬股股票存入中國證券登記結算香港","url":"https://stock-news.laohu8.com/highlight/detail?id=2641193294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641193294?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 08:11","pubTimestamp":1780618293,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，6月4日，维立志博-B(09887)出现仓位异动，存仓市值总计14.86亿港元，占比16.86%。该公司股东将2584.62万股股票存入中国证券登记结算香港，持股比例减少59.44%。5月20日，维立志博发布公告，公司已指示受托人根据H股奖励计划规则，利用总金额最高5000万美元的计划资金按当时的市价通过公开市场交易购入额外H股。受托人过往已根据H股奖励计划规则按公司指示于2025年通过公开市场交易购入若干H股。上述购入的目标股份将用作在H股奖励计划项下相关归属条件达成时授予受让人的奖励股份来源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","HK0000500386.USD","09887","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105301071","title":"維立志博-B5月股份變動月報表：股本維持不變","url":"https://stock-news.laohu8.com/highlight/detail?id=1105301071","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105301071?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 17:35","pubTimestamp":1780306558,"startTime":"0","endTime":"0","summary":"2026年6月1日，南京维立志博生物科技有限公司发布2026年5月股份变动月报表。公告显示，截至2026年5月31日，公司已发行股份数量及注册股本均保持稳定，未发生新增发行、回购或注销等变动事项。维立志博-B确认已遵照香港联交所《上市规则》及适用法律法规的要求，公告由公司联席公司秘书左洪刚签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651160","title":"維立志博(09887.HK)維利信臨床研究結果入選世界肺癌大會口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651160","media":"阿斯达克财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638651160?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 12:10","pubTimestamp":1779941400,"startTime":"0","endTime":"0","summary":"维立志博-B(09887.HK) 公布，评估维利信(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)联合化疗用于治疗一线非小细胞肺癌(NSCLC)的II期临床研究结果入选将于9月12至15日举行的2026年世界肺癌大会(WCLC)口头报告。公司将基于较此前已披露的18例患者数据显著扩大的样本量，展示奥帕替苏米单抗在一线NSCLC中的突破性疗效。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-05-27 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250721150110069_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250721150110069_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526453/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526453/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000500386.USD","09887","BK1161","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636584978","title":"維立志博-B(09887)：受託人擬根據H股獎勵計劃收購最高5000萬美元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636584978","media":"智通财经网","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636584978?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 19:15","pubTimestamp":1779275740,"startTime":"0","endTime":"0","summary":"维立志博-B(09887)发布公告，公司已指示受托人根据H股奖励计划规则，利用总金额最高5000万美元的计划资金按当时的市价通过公开市场交易购入额外H股。受托人过往已根据H股奖励计划规则按公司指示于2025年通过公开市场交易购入若干H股。上述购入的目标股份将用作在H股奖励计划项下相关归属条件达成时授予受让人的奖励股份来源。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174158628","title":"維立志博-B授出信託人指令，以最高5000萬美元購買H股作為獎勵計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1174158628","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174158628?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 19:13","pubTimestamp":1779275605,"startTime":"0","endTime":"0","summary":"维立志博-B已授权信托人根据其H股奖励计划，动用不超过5000万美元的资金在二级市场购买H股。\n该举措旨在为公司的股权激励计划提供股份来源，彰显管理层对长期发展的信心。通过信托人购股并持有，公司可在未来向符合资格的参与者授予股份奖励，以此绑定核心团队利益，推动公司价值持续增长。\n此次购股计划将按照相关市场规则及公司章程执行，具体购买时间、价格及数量将由信托人依据市场情况独立操作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","09887","BK1161","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863428","title":"港股異動 | 維立志博-B(09887)早盤升逾4% 維利信™治療晚期肺外神經內分泌癌III期臨床研究獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863428","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636863428?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 09:53","pubTimestamp":1779155590,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B早盘涨超4%，截至发稿，涨3.21%，报64.35港元，成交额897.51万港元。消息面上，5月19日，维立志博-B发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","HK0000252152.HKD","HK0000252160.HKD","09887","III","HK0000500386.USD","BK4134","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022270","title":"維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)治療晚期肺外神經內分泌癌的III期臨床研究獲得CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636022270?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 07:18","pubTimestamp":1779146304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。奥帕替苏米单抗已在肺外神经内分泌癌、非小细胞肺癌、小细胞肺癌及胆道癌四个适应症的注册性或II 期临床试验中展示出全球首创或同类最优潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","LU1223083913.SGD","BK4017","BK4023","PD","III","HK0000252152.HKD","LU1223082196.USD","LU1169590202.USD","LU1223082519.USD","09887","CDE","HK0000252160.HKD","BK4134","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178121731","title":"一周港股牛熊榜 |  金輝控股飆152%領跑，京西國際、天岳先進升逾六成強勢爆發","url":"https://stock-news.laohu8.com/highlight/detail?id=1178121731","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178121731?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 17:43","pubTimestamp":1778838189,"startTime":"0","endTime":"0","summary":"今日股价显著放量，收盘升205%，成交额超10亿港元。京西国际于5月10日晚间发布公告，披露控股股东京西智行集团告知，其与立讯精密订立买卖协议，立讯精密将收购京西智行集团全部股权，从而间接持有京西国际约59.50%股份，有望成为其最终控股股东。次日股价再升约13.60%，两个交易日累计升逾60%。受金价回软拖累，港股黄金股板块普遍走弱，灵宝黄金本周跌幅逾20%，领跌黄金板块。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09900","09887","09993","01236","00326","00068","02631","02339","03330","02658"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":108,"code":"91000000","status":"200"}]}}